journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Nuclear Medicine and Molecular Imaging

journal
https://www.readbyqxmd.com/read/28337529/the-impact-of-repeated-cycles-of-radioligand-therapy-using-177-lu-lu-psma-617-on-renal-function-in-patients-with-hormone-refractory-metastatic-prostate-cancer
#1
Anna Yordanova, Anja Becker, Elisabeth Eppard, Stefan Kürpig, Christian Fisang, Georg Feldmann, Markus Essler, Hojjat Ahmadzadehfar
BACKGROUND: [(177)Lu]Lu-PSMA-617 is a well-tolerated therapy for the treatment of metastatic prostate cancer. However, because of the mainly renal excretion of the tracer, the kidneys are one of the most limiting organs. The purpose of this study was to examine the post-therapeutic changes in renal function over time and to identify risk factors for developing renal toxicity. We also tested the reliability of markers for renal function monitoring. METHODS: Fifty-five patients with castrate-resistant metastatic prostate cancer treated with at least three cycles of [(177)Lu]Lu-PSMA-617 were investigated...
March 23, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28331955/reply-to-predicting-the-outcome-of-peptide-receptor-radionuclide-therapy-in-neuroendocrine-tumors-the-importance-of-dual-tracer-imaging
#2
LETTER
Giovanni Paganelli, Maddalena Sansovini, Emanuela Scarpi
No abstract text is available yet for this article.
March 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28331954/individualised-177-lu-dotatate-treatment-of-neuroendocrine-tumours-based-on-kidney-dosimetry
#3
Anna Sundlöv, Katarina Sjögreen-Gleisner, Johanna Svensson, Michael Ljungberg, Tomas Olsson, Peter Bernhardt, Jan Tennvall
PURPOSE: To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED). METHOD: Treatment was given with repeated cycles of 7.4 GBq (177)Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry was performed in all patients after each cycle using a hybrid method (SPECT + planar imaging)...
March 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28331953/value-of-fdg-pet-scans-of-non-demented-patients-in-predicting-rates-of-future-cognitive-and-functional-decline
#4
Nare Torosyan, Kelsey Mason, Magnus Dahlbom, Daniel H S Silverman
PURPOSE: The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI). METHODS: Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer's Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer's disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores...
March 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28326436/reference-region-selection-and-the-association-between-the-rate-of-amyloid-accumulation-over-time-and-the-baseline-amyloid-burden
#5
Janusch Blautzik, Matthias Brendel, Julia Sauerbeck, Sebastian Kotz, Franziska Scheiwein, Peter Bartenstein, John Seibyl, Axel Rominger
Relative quantitative analysis of amyloid plaque burden in Alzheimer's disease (AD) patients can be reported as standardized uptake value ratio (SUVR) from positron emission tomography (PET). Here, the SUVR is the ratio of the mean amyloid radioligand retention in a composite (COMP) neocortical volume of interest (VOI) to that in a reference VOI, such as the cerebellum, brainstem (BST)/pons, or white matter (WM). Some longitudinal PET investigations show that the rate of amyloid accumulation to follow-up has an inverted U relationship with baseline amyloid SUVR relative to cerebellar or brainstem/pons reference VOIs...
March 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28321471/feasibility-of-in-vivo-18-f-florbetaben-pet-mr-imaging-of-human-carotid-amyloid-%C3%AE
#6
Jan Bucerius, Henryk Barthel, Solveig Tiepolt, Peter Werner, Judith C Sluimer, Joachim E Wildberger, Marianne Patt, Swen Hesse, Hermann-Josef Gertz, Erik A L Biessen, Felix M Mottaghy, Osama Sabri
PURPOSE: Amyloid-beta (Aβ) peptides are involved in the inflammatory pathology of atherosclerosis. (18)F-Florbetaben is a PET tracer for clinical imaging of cerebral Aβ plaques in Alzheimer's disease (AD). We sought to determine whether specific uptake of (18)F-florbetaben in the carotid arteries can be identified using a fully integrated hybrid PET/MRI system and whether this uptake is associated with clinical cardiovascular disease (CVD) risk factors. METHODS: Carotid (18)F-florbetaben uptake was quantified as the mean of the maximum target-to-background ratio (meanTBRmax) in 40 cognitively impaired subjects (age 68...
March 21, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28315949/-89-zr-onartuzumab-pet-imaging-of-c-met-receptor-dynamics
#7
Martin Pool, Anton G T Terwisscha van Scheltinga, Arjan Kol, Danique Giesen, Elisabeth G E de Vries, Marjolijn N Lub-de Hooge
PURPOSE: c-MET and its ligand hepatocyte growth factor are often dysregulated in human cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or emergence of resistance. Noninvasive visualization of c-MET dynamics could therefore potentially guide c-MET-directed therapies. We investigated the feasibility of (89)Zr-labelled one-armed c-MET antibody onartuzumab PET for detecting relevant changes in c-MET levels induced by c-MET-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib resistance or heat shock protein-90 (HSP90) inhibitor NVP-AUY-922 treatment in human non-small-cell lung cancer (NSCLC) xenografts...
March 19, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28315948/-18f-fmiso-pet-study-of-hypoxia-in-gliomas-before-surgery-correlation-with-molecular-markers-of-hypoxia-and-angiogenesis
#8
Lien Bekaert, Samuel Valable, Emmanuèle Lechapt-Zalcman, Keven Ponte, Solène Collet, Jean-Marc Constans, Guénaëlle Levallet, Karim Bordji, Edwige Petit, Pierre Branger, Evelyne Emery, Alain Manrique, Louisa Barré, Myriam Bernaudin, Jean-Sébastien Guillamo
PURPOSE: Hypoxia in gliomas is associated with tumor resistance to radio- and chemotherapy. However, positron emission tomography (PET) imaging of hypoxia remains challenging, and the validation of biological markers is, therefore, of great importance. We investigated the relationship between uptake of the PET hypoxia tracer [18F]-FMISO and other markers of hypoxia and angiogenesis and with patient survival. PATIENTS AND METHODS: In this prospective single center clinical study, 33 glioma patients (grade IV: n = 24, III: n = 3, and II: n = 6) underwent [18F]-FMISO PET and MRI including relative cerebral blood volume (rCBV) maps before surgery...
March 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28315947/impact-of-18-f-fdg-pet-ct-on-surgical-management-in-patients-with-advanced-melanoma-an-outcome-based-analysis
#9
Andrea Forschner, Susann-Cathrin Olthof, Brigitte Gückel, Peter Martus, Werner Vach, Christian la Fougère, Konstantin Nikolaou, Ulrike Keim, Thomas Kurt Eigentler, Claus Garbe, Christina Pfannenberg
PURPOSE: To evaluate the influence of (18)F-FDG-PET/CT on clinical decision making and outcome in advanced melanoma patients planned for radical metastasectomy. METHODS AND MATERIALS: A cohort of 333 patients with mainly stage III/IV melanoma having a PET/CT for clinical reasons was prospectively enrolled in our oncologic PET/CT registry between 2013 and 2015. Referring physicians completed questionnaires regarding their intended management for each patient before and after PET/CT...
March 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28314910/the-relationship-between-the-dopaminergic-system-and-depressive-symptoms-in-cervical-dystonia
#10
E Zoons, M A J Tijssen, Y E M Dreissen, J D Speelman, M Smit, J Booij
PURPOSE: Cervical dystonia (CD) is associated with tremor/jerks (50%) and psychiatric complaints (17-70%). The dopaminergic system has been implicated in the pathophysiology of CD in animal and imaging studies. Dopamine may be related to the motor as well as non-motor symptoms of CD. CD is associated with reduced striatal dopamine D2/3 (D2/3) receptor and increased dopamine transporter (DAT) binding. There are differences in the dopamine system between CD patients with and without jerks/tremor and psychiatric symptoms...
March 17, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28303300/consequences-of-radiopharmaceutical-extravasation-and-therapeutic-interventions-a-systematic-review
#11
REVIEW
Jochem van der Pol, Stefan Vöö, Jan Bucerius, Felix M Mottaghy
PURPOSE: Radiopharmaceutical extravasation can potentially lead to severe soft tissue damage, but little is known about incidence, medical consequences, possible interventions, and effectiveness of these. The aims of this study are to estimate the incidence of extravasation of diagnostic and therapeutic radiopharmaceuticals, to evaluate medical consequences, and to evaluate medical treatment applied subsequently to those incidents. METHODS: A sensitive and elaborate literature search was performed in Embase and PubMed using the keywords "misadministration", "extravasation", "paravascular infiltration", combined with "tracer", "radionuclide", "radiopharmaceutical", and a list of keywords referring to clinically used tracers (i...
March 16, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28293706/coronary-atherosclerotic-burden-vs-coronary-vascular-function-in-diabetic-and-nondiabetic-patients-with-normal-myocardial-perfusion-a-propensity-score-analysis
#12
Roberta Assante, Wanda Acampa, Emilia Zampella, Parthiban Arumugam, Carmela Nappi, Valeria Gaudieri, Mariarosaria Panico, Mario Magliulo, Christine M Tonge, Mario Petretta, Alberto Cuocolo
PURPOSE: To assess the relationship between coronary atherosclerotic burden and vascular function in diabetic and nondiabetic patients after balancing for coronary risk factors. METHODS: We studied 672 patients without overt coronary artery disease and normal myocardial perfusion on stress (82)Rb PET/CT imaging. To account for differences in baseline characteristics between diabetic patients and nondiabetic patients, we created a propensity score-matched cohort considering clinical variables and coronary risk factors...
March 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28293705/idh-mutation-is-paradoxically-associated-with-higher-18-f-fdopa-pet-uptake-in-diffuse-grade-ii-and-grade-iii-gliomas
#13
A Verger, Ph Metellus, Q Sala, C Colin, E Bialecki, D Taieb, O Chinot, D Figarella-Branger, E Guedj
PURPOSE: The World Health Organization Classification of Tumors of the Central Nervous System has recently been updated by the integration of diagnostic and prognostic molecular parameters, giving pivotal attention to IDH mutation as a favourable factor. Amino acid PET is increasingly used in the management of gliomas, but its prognostic value is a matter of debate. The aim of this study was to assess the relationship between IDH mutation and (18)F-FDOPA uptake on PET in newly diagnosed gliomas...
March 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28283702/-68-ga-psma-pet-ct-joint-eanm-and-snmmi-procedure-guideline-for-prostate-cancer-imaging-version-1-0
#14
Wolfgang P Fendler, Matthias Eiber, Mohsen Beheshti, Jamshed Bomanji, Francesco Ceci, Steven Cho, Frederik Giesel, Uwe Haberkorn, Thomas A Hope, Klaus Kopka, Bernd J Krause, Felix M Mottaghy, Heiko Schöder, John Sunderland, Simon Wan, Hans-Jürgen Wester, Stefano Fanti, Ken Herrmann
The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of (68)Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of (68)Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.
March 10, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28283701/predicting-the-outcome-of-peptide-receptor-radionuclide-therapy-in-neuroendocrine-tumors-the-importance-of-dual-tracer-imaging
#15
LETTER
Paolo Zanotti-Fregonara, Clément Morgat, Christophe Champion, Elif Hindié
No abstract text is available yet for this article.
March 10, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28280856/comparison-of-standard-and-delayed-imaging-to-improve-the-detection-rate-of-68-ga-psma-i-t-pet-ct-in-patients-with-biochemical-recurrence-or-prostate-specific-antigen-persistence-after-primary-therapy-for-prostate-cancer
#16
Sebastian Schmuck, Stefan Nordlohne, Christoph-A von Klot, Christoph Henkenberens, Jan M Sohns, Hans Christiansen, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin
PURPOSE: The aim of this study was to assess the value of dual-time point imaging in PET/CT for detection of biochemically recurrent or persistent prostate cancer, using the prostate-specific membrane antigen (PSMA) ligand [(68)Ga]PSMA I&T. METHODS: 240 patients who underwent a [(68)Ga]PSMA I&T PET/CT in the context of biochemical relapse of prostate cancer were included in this retrospective analysis. Imaging consisted of a standard whole-body PET/CT (1 h p.i.), followed by delayed (3 h p...
March 9, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28280855/repeated-psma-targeting-radioligand-therapy-of-metastatic-prostate-cancer-with-131-i-mip-1095
#17
Ali Afshar-Oromieh, Uwe Haberkorn, Christian Zechmann, Thomas Armor, Walter Mier, Fabian Spohn, Nils Debus, Tim Holland-Letz, John Babich, Clemens Kratochwil
PURPOSE: Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies. METHODS: Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with (131)I-MIP-1095. Twenty-three patients received a second, and three patients a third dose, timed at PSA progression after an initial response to the preceding therapy...
March 9, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28265739/risk-stratifying-capacity-of-pet-ct-metabolic-tumor-volume-in-stage-iiia-non-small-cell-lung-cancer
#18
Joshua H Finkle, Stephanie Y Jo, Mark K Ferguson, Hai-Yan Liu, Chenpeng Zhang, Xuee Zhu, Cindy Yuan, Yonglin Pu
OBJECTIVES: Stage IIIA non-small cell lung cancer (NSCLC) is heterogeneous in tumor burden, and its treatment is variable. Whole-body metabolic tumor volume (MTVWB) has been shown to be an independent prognostic index for overall survival (OS). However, the potential of MTVWB to risk-stratify stage IIIA NSCLC has previously been unknown. If we can identify subgroups within the stage exhibiting significant OS differences using MTVWB, MTVWB may lead to adjustments in patients' risk profile evaluations and may, therefore, influence clinical decision making regarding treatment...
March 7, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28265738/radiolabeled-pertuzumab-for-imaging-of-human-epidermal-growth-factor-receptor-2-expression-in-ovarian-cancer
#19
Dawei Jiang, Hyung-Jun Im, Haiyan Sun, Hector F Valdovinos, Christopher G England, Emily B Ehlerding, Robert J Nickles, Dong Soo Lee, Steve Y Cho, Peng Huang, Weibo Cai
PURPOSE: Human epidermal growth factor receptor 2 (HER2) is over-expressed in over 30% of ovarian cancer cases, playing an essential role in tumorigenesis and metastasis. Non-invasive imaging of HER2 is of great interest for physicians as a mean to better detect and monitor the progression of ovarian cancer. In this study, HER2 was assessed as a biomarker for ovarian cancer imaging using (64)Cu-labeled pertuzumab for immunoPET imaging. METHODS: HER2 expression and binding were examined in three ovarian cancer cell lines (SKOV3, OVCAR3, Caov3) using in vitro techniques, including western blot and saturation binding assays...
March 6, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28261749/intra-image-referencing-for-simplified-assessment-of-her2-expression-in-breast-cancer-metastases-using-the-affibody-molecule-aby-025-with-pet-and-spect
#20
Dan Sandberg, Vladimir Tolmachev, Irina Velikyan, Helena Olofsson, Anders Wennborg, Joachim Feldwisch, Jörgen Carlsson, Henrik Lindman, Jens Sörensen
PURPOSE: In phase I/II-studies radiolabelled ABY-025 Affibody molecules identified human epidermal growth factor receptor 2 (HER2) expression in breast cancer metastases using PET and SPECT imaging. Here, we wanted to investigate the utility of a simple intra-image normalization using tumour-to-reference tissue-ratio (T/R) as a HER2 status discrimination strategy to overcome potential issues related to cross-calibration of scanning devices. METHODS: Twenty-three women with pre-diagnosed HER2-positive/negative metastasized breast cancer were scanned with [(111)In]-ABY-025 SPECT/CT (n = 7) or [(68)Ga]-ABY-025 PET/CT (n = 16)...
March 6, 2017: European Journal of Nuclear Medicine and Molecular Imaging
journal
journal
20104
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"